Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Kelly DL, Gorelick DA, Conley RR, Boggs DL, Linthicum J, Liu F, Feldman S, Ball MP, Wehring HJ, McMahon RP, Huestis MA, Heishman SJ, Warren KR, Buchanan RW. Kelly DL, et al. Among authors: linthicum j. J Clin Psychopharmacol. 2011 Feb;31(1):86-91. doi: 10.1097/JCP.0b013e318204825b. J Clin Psychopharmacol. 2011. PMID: 21192149 Free PMC article. Clinical Trial.
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Warren KR, Buchanan RW, Feldman S, Conley RR, Linthicum J, Ball MP, Liu F, McMahon RP, Gorelick DA, Huestis MA, Kelly DL. Warren KR, et al. Among authors: linthicum j. J Clin Psychopharmacol. 2013 Feb;33(1):118-20. doi: 10.1097/JCP.0b013e3182793843. J Clin Psychopharmacol. 2013. PMID: 23277241 Free PMC article. Clinical Trial. No abstract available.
Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study.
Lee MR, Wehring HJ, McMahon RP, Linthicum J, Cascella N, Liu F, Bellack A, Buchanan RW, Strauss GP, Contoreggi C, Kelly DL. Lee MR, et al. Among authors: linthicum j. Schizophr Res. 2013 Apr;145(1-3):110-5. doi: 10.1016/j.schres.2013.01.001. Epub 2013 Feb 13. Schizophr Res. 2013. PMID: 23415472 Free PMC article. Clinical Trial.
Cannabis withdrawal in chronic cannabis users with schizophrenia.
Boggs DL, Kelly DL, Liu F, Linthicum JA, Turner H, Schroeder JR, McMahon RP, Gorelick DA. Boggs DL, et al. J Psychiatr Res. 2013 Feb;47(2):240-5. doi: 10.1016/j.jpsychires.2012.10.010. Epub 2012 Nov 10. J Psychiatr Res. 2013. PMID: 23146560 Free PMC article.
Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder.
Koola MM, Gorelick DA, McMahon RP, Liu F, Huestis MA, Linthicum J, Feldman SM, Warren KR, Wehring HJ, Kelly DL. Koola MM, et al. Among authors: linthicum j. Schizophr Res. 2014 Jan;152(1):315-6. doi: 10.1016/j.schres.2013.11.035. Epub 2013 Dec 12. Schizophr Res. 2014. PMID: 24333005 Free PMC article. No abstract available.
Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia.
Lee MR, Wehring HJ, McMahon RP, Liu F, Linthicum J, Verbalis JG, Buchanan RW, Strauss GP, Rubin LH, Kelly DL. Lee MR, et al. Among authors: linthicum j. Schizophr Res. 2016 Apr;172(1-3):165-8. doi: 10.1016/j.schres.2016.02.014. Epub 2016 Feb 12. Schizophr Res. 2016. PMID: 26879587 Free PMC article. Clinical Trial.
24 results